Next-generation Glioblastoma Multiforme Therapies Based On Multistage Delivery Nanovectors
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Nanomedicine provides novel therapies with enhanced treatment success and reduced side effects, which improve the patient’s quality of life. Drug delivery systems that are able to treat highly drug-resistant tumours such as glioblastoma multiforme (GBM) are a key target for nanomedicine-based therapies. We will investigate a new GBM treatment by developing a multistage delivery nanovector to selectively carry and release a combination of chemical and physical therapeutics.
Understanding Relapse In Posttraumatic Stress Disorder: An Investigation Of Return Of Fear.
Funder
National Health and Medical Research Council
Funding Amount
$255,014.00
Summary
Posttraumatic Stress Disorder (PTSD) is common and results in significant impairment. There are effective psychological treatments for PTSD, yet relapse following treatment remains high. The proposed research will involve a series of experiments and observational studies to better understand the process that lead to relapse in patients receiving treatment for PTSD. The findings of these studies will assist in modifying treatment to ensure that symptom gains are maintained following treatment.
Improving The Therapeutic Use Of Anti-infective Agents: Application Of Pharmacometrics For Rational Dosing Regimen Design
Funder
National Health and Medical Research Council
Funding Amount
$313,390.00
Summary
There is no field of medicine in which the individualisation of medicines is more important than in infectious diseases – appropriate doses must be administered to maximise efficacy and to minimise side effects and the emergence of drug-resistance. This fellowship will use the emerging science of pharmacometrics to investigate factors contributing to the variability in response to anti-infective medications and to optimise dosing regimens for the best use of these drugs in clinical practice.
Identifying Mechanisms Of Resistance To Novel Hormonal Agents In Patients With Castrate-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$420,004.00
Summary
I am a medical oncologist focused on prostate cancer, a disease which kills over 3000 Australian men every year. Recent studies have shown that new hormone treatments help men with advanced prostate cancer live longer. Unfortunately, while these drugs are effective when first started, prostate cancers eventually become resistant to them and start growing again. By looking at why these drugs stop working, I hope to find better treatments for Australian men with advanced prostate cancer.
RNA Interference And Retigabine Therapy Protect Against Hereditary Hearing Loss
Funder
National Health and Medical Research Council
Funding Amount
$370,522.00
Summary
The preservation of hearing function is central to the treatment of individuals who are genetically predisposed to hearing loss. At present only synthetic hearing aids and cochlear implants can provide functional improvement, albeit sub-optimal. The studies described here will seek to prevent hearing loss by reducing the damaging effects of defective genes. Gene therapies that reduce the effect of these defective genes and a drug that enhances the activity of functional genes will be developed.
Neurodevelopmental Outcomes After Novel Interventions In Newborn Infants
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
Children who were sick in the newborn period or born preterm are at increased risk of abnormal development, particularly problems with their ability to walk, think and learn. This research will assess how new treatments affect sick newborns’ later development. For example, giving preterm babies healthy germs, or probiotics, decreases a serious bowel infection, called necrotising enterocolitis or NEC. This research will find out if they also help preterm brain development when the children are 2 ....Children who were sick in the newborn period or born preterm are at increased risk of abnormal development, particularly problems with their ability to walk, think and learn. This research will assess how new treatments affect sick newborns’ later development. For example, giving preterm babies healthy germs, or probiotics, decreases a serious bowel infection, called necrotising enterocolitis or NEC. This research will find out if they also help preterm brain development when the children are 2 years old.Read moreRead less